Submit Content Become a member

Predictive diagnostics pioneer Proteomics International Laboratories (ASX: PIQ) has engaged the medical device sales agency, Growth Medics, to assist with the identification and selection of EU alliance partners for its PromarkerD predictive test for diabetic kidney disease.

Growth Medics will assist in the identification, recruitment and management of new partners and customers in Europe. Growth Medics are an international medical device sales accelerator and have a proven track record assisting medical device and diagnostic companies achieve market penetration, and the digital marketing experience required for Proteomics International’s global go-to-market strategy.

Growth Medics will also provide business development, marketing and administrative support for Proteomics International and PromarkerD from its office in the Netherlands.

Its role will extend to attending trade shows on behalf of Proteomics International, customer service and training. Growth Medics will initially target new licensing and sales opportunities in the Netherlands, Belgium, Italy and Spain.

Diabetes is a ‘silent pandemic’ and one of the major health challenges of our generation. Diabetic kidney disease (DKD) is a serious complication arising from diabetes which can lead to other health issues such as high blood pressure, heart disease, and ultimately kidney failure. There are 61 million people in Europe living with diabetes1. The total expenditure in the European region on the advanced treatment of diabetes and its complications was EUR176 billion (19.6% of global expenditure) in 20212.

“We believe Growth Medics is an ideal partner to drive the commercialisation of PromarkerD through Europe due to their extensive market knowledge, proven track record, regulatory expertise, and strong relationships with key stakeholders. Their multilingual and multicultural capabilities ensure targeted sales and marketing strategies. This is a material development in our expansion strategy for PromarkerD across the diverse European market,” Proteomics International Managing Director Dr Richard Lipscombe said.

Rate article from Colin Hay: